Longevity Science

In 2013, Lopez-Otin and colleagues published a landmark paper identifying nine hallmarks of aging that contribute to the aging phenotype: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. A 2023 update added four additional hallmarks including disabled macroautophagy and chronic inflammation.

Understanding these hallmarks has given researchers specific molecular targets for longevity interventions, moving the field from general wellness into precise biological engineering.

Senescent cells are cells that have stopped dividing but refuse to die. They accumulate with age and secrete a toxic cocktail of inflammatory molecules called the senescence-associated secretory phenotype (SASP). This chronic inflammation drives many aging-associated conditions including cardiovascular disease, neurodegeneration, and frailty.

Senolytics -- drugs that selectively eliminate senescent cells -- are among the most actively studied longevity interventions. Early human trials have shown safety and some biomarker changes. Whether they extend healthy lifespan in humans remains under investigation.

Epigenetics refers to changes in gene expression that do not alter the DNA sequence itself. The epigenome -- the pattern of chemical modifications to DNA and associated proteins -- changes with age in highly consistent ways. Epigenetic clocks, pioneered by Steve Horvath and others, use these patterns to estimate biological age with accuracy that often exceeds chronological age as a predictor of health outcomes.

Cellular reprogramming technologies work by resetting epigenetic patterns. In animal studies, partial reprogramming has restored youthful gene expression without full dedifferentiation (which would erase cell identity).

Several metabolic signaling pathways are directly linked to lifespan in model organisms. The mTOR pathway regulates cellular growth and metabolism and is inhibited by rapamycin, which extends lifespan in multiple species. The AMPK pathway, activated by exercise and caloric restriction, promotes cellular maintenance processes including autophagy. Sirtuins -- NAD-dependent deacetylases -- regulate DNA repair, inflammation, and metabolic function.

Interventions targeting these pathways include caloric restriction, metformin, rapamycin, and NAD precursors. Human evidence for lifespan extension is not established for any of these. Evidence for improved healthspan markers varies.

Machine learning and AI are accelerating longevity research by enabling faster target identification, drug candidate screening, and biomarker analysis. AI models trained on large genomic and proteomic datasets can identify aging-associated molecular targets that would take decades to find through conventional approaches. Companies like BioAge Labs and Insilico Medicine are building AI-first longevity drug discovery platforms.